Safety of saxagliptin: Rationale for and design of a series of postmarketing observational studies

Vincent Lo Re, Kevin Haynes, Eileen E. Ming, Jennifer Wood Ives, Laura N. Horne, Kimberly Fortier, Dena M. Carbonari, Sean Hennessy, Serena Cardillo, Peter P. Reese, K. Rajender Reddy, David Margolis, Andrea Apter, Stephen E. Kimmel, Jason Roy, Cristin P. Freeman, Hanieh Razzaghi, Crystal N. Holick, Daina B. Esposito, Tjeerd Pieter Van StaaHarshvinder Bhullar, Brian L. Strom

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Purpose: To describe the design and rationale of a series of postmarketing studies to examine the safety of saxagliptin, an oral dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus, in real-world settings. Methods: We are conducting a series of retrospective cohort studies using two UK (General Practice Research Database, and The Health Improvement Network) and two US (Medicare, HealthCore Integrated Research DatabaseSM) data sources. The primary outcomes of interest will include (i) hospitalization with acute liver failure, (ii) hospitalization for acute kidney injury, (iii) hospitalization for severe hypersensitivity reactions, (iv) hospitalization for severe infections, (v) hospitalization with infections associated with T-lymphocyte dysfunction (i.e., herpes zoster, tuberculosis, or nontuberculous mycobacteria), and (vi) major cardiovascular events. Diagnosis codes for the outcomes of interest will be validated by medical record review within each data source. Projected use and estimated incidence rates of outcomes of interest suggest there will be at least 80% statistical power to detect a minimum hazard ratio of 1.5 for major cardiovascular events, 2.0 for acute kidney injury and severe infections, 2.4 for acute liver failure, and 4.0 for severe hypersensitivity reactions. Results: Forthcoming. Conclusions: This postmarketing safety assessment will provide important information regarding the safety of saxagliptin and could potentially identify important dipeptidyl peptidase-4 inhibitor class effects. The methods described may be useful to others planning similar evaluations.

Original languageEnglish (US)
Pages (from-to)1202-1215
Number of pages14
JournalPharmacoepidemiology and drug safety
Issue number11
StatePublished - Nov 1 2012

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Pharmacology (medical)


  • Adverse event
  • Diabetes mellitus
  • Dipeptidyl peptidase-4 inhibitor
  • Pharmacoepidemiology
  • Saxagliptin

Fingerprint Dive into the research topics of 'Safety of saxagliptin: Rationale for and design of a series of postmarketing observational studies'. Together they form a unique fingerprint.

Cite this